On Feb. 29, 2024, the federal government introduced Bill C-64 — the long-awaited National Pharmacare Program. It was an historic announcement, with diabetes medications and a device fund included in the first phase.

For more than four million people diagnosed with diabetes in Canada, this looked like a turning point — a chance to finally break down cost barriers to life-saving treatments.

But hope is fragile and that cautious optimism is already under threat. Now we need to act to make sure pharmacare in Canada doesn’t leave millions of Canadians with diabetes behind.

Diabetes Canada welcomes the government’s recognition that people with diabetes need better access to medications and devices. We know this is urgent. For many, the cost of treatment is the difference between good health a

See Full Page